Prospective comprehensive profiling of immune responses to COVID-19 vaccination in patients on zanubrutinib therapy
- Author(s)
- Nguyen, THO; Lim, C; Lasica, M; Whitechurch, A; Tennakoon, S; Saunders, NR; Allen, LF; Rowntree, LC; Chua, BY; Kedzierski, L; Tan, HX; Wheatley, AK; Kent, SJ; Karapanagiotidis, T; Nicholson, S; Williamson, DA; Slavin, MA; Tam, CS; Kedzierska, K; Teh, BW;
- Journal Title
- eJHaem
- Publication Type
- Research article
- Abstract
- Zanubrutinib-treated and treatment-naive patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID-19 vaccination. Overall, 45 patients (median 72 years old) were recruited; the majority were male (71%), had CLL (76%) and were on zanubrutinib (78%). Seroconversion rates were 65% and 77% following two and three doses, respectively. CD4(+) and CD8(+) T-cell response rates increased with third dose. In zanubrutinib-treated patients, 86% developed either a humoral or cellular response. Patients on zanubrutinib developed substantial immune responses following two COVID-19 vaccine doses, which further improved following a third dose.
- Publisher
- Wiley
- Department(s)
- Infectious Diseases; Clinical Haematology
- PubMed ID
- 36819189
- Publisher's Version
- https://doi.org/10.1002/jha2.639
- Open Access at Publisher's Site
https://doi.org/10.1002/jha2.639- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-13 07:55:07
Last Modified: 2023-06-13 07:56:08